Psyence Biomedical Finalizes 1-for-6.25 Reverse Stock Split Effective February 2nd After Delay

summarizeSummary

Psyence Biomedical Ltd. announced the effective date of its 1-for-6.25 reverse stock split, which will commence trading on a post-consolidated basis on February 2, 2026, following a brief delay.

check_boxKey Events · Financing and Capital Events · PBM

• Reverse Stock Split Effective Date Set

  The 1-for-6.25 share consolidation will become effective for trading on a post-consolidated basis on February 2, 2026.

• Previous Delay Acknowledged

  The company confirmed a delay in the reverse stock split's effectiveness, which was initially planned for January 20, 2026, as previously disclosed on January 14, 2026.

• Share Count Reduction

  The number of issued and outstanding common shares will decrease from 6,388,604 to 1,022,177 post-consolidation.

• Ongoing Compliance Efforts

  This marks another reverse stock split for the company, following a 1-for-7.97 split in May 2025, indicating continued efforts to meet Nasdaq listing requirements.

auto_awesomeAnalysis · PBM · Life Sciences

This filing confirms the implementation of a 1-for-6.25 reverse stock split, a critical measure for Psyence Biomedical to maintain its Nasdaq listing compliance. The delay in the effective date, initially announced for January 20, 2026, suggests operational challenges or last-minute considerations. This marks another significant share consolidation for the micro-cap company, following a 1-for-7.97 split in May 2025 and a more aggressive 1-for-250 split proposal earlier this month, highlighting persistent struggles with its share price and exchange requirements. Investors should monitor the stock's performance post-split and the company's ability to sustain compliance.